<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med Exp</journal-id><journal-id journal-id-type="iso-abbrev">Intensive Care Med Exp</journal-id><journal-title-group><journal-title>Intensive Care Medicine Experimental</journal-title></journal-title-group><issn pub-type="epub">2197-425X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4796881</article-id><article-id pub-id-type="publisher-id">310</article-id><article-id pub-id-type="doi">10.1186/2197-425X-3-S1-A164</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>High-flow oxygen therapy for extubation failure prevention in high-risk critically ill patients: a randomized multicenter trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fernandez</surname><given-names>R</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Subira</surname><given-names>C</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Frutos</surname><given-names>F</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Rialp</surname><given-names>G</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Laborda</surname><given-names>C</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Masclans</surname><given-names>JR</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Hernandez</surname><given-names>G</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Hospital Sant Joan de Deu / Fundacio Althaia, Manresa, Spain </aff><aff id="Aff2"><label/>Universitat Internacional de Catalunya. CIBERES, Barcelona, Spain </aff><aff id="Aff3"><label/>H. Universitario de Getafe, Madrid, Spain </aff><aff id="Aff4"><label/>H. Son Llatzer, Mallorca, Spain </aff><aff id="Aff5"><label/>H. U. Valle Hebron, Barcelona, Spain </aff><aff id="Aff6"><label/>H. Virgen de la Salud, Toledo, Spain </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 1</issue><issue-sponsor>The publication charges for this supplement were funded by Intensive Care Medicine Experimental.</issue-sponsor><elocation-id>A164</elocation-id><permissions><copyright-statement>&#x000a9; Fernandez et al.; 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><conference><conf-name>ESICM LIVES 2015</conf-name><conf-loc>Berlin, Germany</conf-loc><conf-date>3-7 October 2015</conf-date><string-conf><uri>http://www.esicm.org/</uri></string-conf></conference><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Extubation failure in critically ill patients has associated morbidity, but it cannot be safely predicted or avoided. Preventive NIMV has proved beneficial only in hypercapnic patients. We hypothesized that High-flow oxygen therapy may reduce postextubation respiratory failure due to gas humidification, avoidance of lung collapse by moderate PEEP, and work of breathing reduction by dead-space washing.</p></sec><sec id="Sec2"><title>Objectives</title><p>Our objective was to reduce postextubation respiratory failure with High-flow in high-risk patients.</p></sec><sec id="Sec3"><title>Methods</title><p>Randomized multicenter trial in patients who successfully passed a spontaneous breathing trial. Only patients with criteria for high-risk of failure were randomized to receive conventional oxygen or High-flow oxygen (Optiflow&#x000ae;: Fisher Paykel) for 24 hours post-extubation. Primary outcome was respiratory failure within 72 hours postextubation. Secondary outcome were: reintubation, ICU and hospital length of stay, and survival. Statistical analysis included multiple logistic regression models.</p></sec><sec id="Sec4"><title>Results</title><p>The study was stopped after 18 months due to low recruitment. We enrolled 155 patients: 77 with conventional and 78 with High-flow oxygen. Groups were very similar at enrollment. All patients tolerated the High-flow system. We found the projected reduction in postextubation respiratory failure (20.5% vs. 27.3%, p = 0.3) that failed to reach statistical significance due to sample size. Similarly, the benefit in reintubation (16.7% vs. 19.5%, p = 0.6) didn&#x000b4;t reach significance. We found no differences in ICU length of stay, hospital length of stay, and survival. By a logistic regression model, we were able to independently associate high-flow with reduction in postextubation respiratory failure (OR 0.4 p = 0.049), by including COPD, cancer, length of MV, obesity, and cardiac failure in the model.</p></sec><sec id="Sec5"><title>Conclusions</title><p>High-flow oxygen therapy for 24-h may reduce postextubation respiratory failure in high-risk critically ill patients.</p></sec></body></article>